Therapeutic Efficacy of Topical Olopatadine 0.1% Versus Ketotifen Fumarate in Allergic Conjunctivitis

Abstract

Objective: To compare the therapeutic efficacy of topical Olopatadine 0.1% versus Ketotifen Fumarate among the patients diagnosed with allergic conjunctivitis at Armed forces institute of ophthalmology.
 Study Design: Prospective comparative study.
 Place and Duration of Study: Armed forces Institute of Ophthalmology, Rawalpindi, from Jan 2020 to Jan 2021.
 Methodology: Patients diagnosed with allergic conjunctivitis by consultant ophthalmologist fulfilling the exclusion/inclusion criteria were included in the study. They were divided into two groups by block randomization with group A receiving Olopatadine 0.1%, while group B just received the Ketotifen Fumarate. Symptoms were assessed on a symptom severity score upon diagnosis before the start of medication and then after 72 hours of treatment by a different consultant ophthalmologist who was unaware of the group of patients.
 Results: A total of 100 patients were included in each group. The mean age of the study participants was 30.944 ± 3.349 years. 148 (74%) patients were males while 52 (26%) were females. The difference in mean score of symptoms in group A was 5.76 ± 1.39 while in group B was 3.33 ± 2.51. Application of t-test revealed that topical Olopatadine 0.1% was superior to Ketotifen Fumarate in reducing the symptoms of acute allergic conjunctivitis on the third day of treatment (p-value<0.001).
 Conclusion: Seasonal allergic conjunctivitis was the commonest type of allergic conjunctivitis seen in our study participants. Topical Olopatadine 0.1% emerged as a better treatment option when compared to Ketotifen Fumarate for immediate management of acute allergic conjunctivitis among patients managed at a tertiary...................

Comparison of olopatadine with ketotifen for allergic conjunctivitis: a meta-analysis study

“…203 publications were identified through the initial search of databases. Ultimately, seven RCTs were included in the meta-analysis [ 6 , 25 – 30 ].…”

Allergic Conjunctivitis Management: Update on Ophthalmic Solutions

“…Olopatadine [80,81] NCT01109485 Superior to ketotifen and superior to levocabastine [99][100][101][102] Common side effects include compared to vehicle, they were well tolerated, and showed an acceptable safety profile [32][33][34]. This cetirizine ophthalmic formulation needs to be used three times a day, as the dosage is one drop in each affected eye every 8 h. It contains BAK (0.01%) as a preservative to guarantee the sterility of the multi-dose formulation.…”